How Tirzepatide Works: Dual GIP/GLP-1 Mechanism Across Diabetes, Obesity, and Heart Disease | Research

The takeaway

Tirzepatide uniquely activates both GIP and GLP-1 receptors, providing glycemic control, weight loss, and cardiorenal benefits, with expanding indications from diabetes to obesity, HFpEF, and MASH.

First dual agonist
Tirzepatide uniquely combines GIP and GLP-1 receptor activation for comprehensive metabolic benefits exceeding either pathway alone

What the researchers found

Tirzepatide's dual GIP/GLP-1 receptor agonism provides comprehensive metabolic benefits across glycemic control, weight loss, cardiorenal protection, and lipid metabolism, with expanding indications to HFpEF and MASH.

Why it matters

Tirzepatide is the fastest-growing diabetes/obesity drug. Understanding its dual mechanism helps clinicians maximize its therapeutic potential.

How the study worked

Narrative review of tirzepatide mechanism of action, pharmacology, and clinical trial evidence across approved and investigational indications.

What this study cannot tell us

Review; no new data. Some indications still investigational. Long-term safety data accumulating.

How to read the evidence

Review synthesizing clinical trial evidence across multiple indications.

When this study was published

Published in 2025.

The bigger picture

Tirzepatide proves that targeting two incretin pathways simultaneously produces benefits greater than either alone — a principle driving the next generation of multi-receptor agonists.

Questions still open

How does tirzepatide compare to emerging triple agonists like retatrutide?
Will cardiovascular outcome trials show mortality benefit?
Should tirzepatide replace semaglutide as first-line therapy?

Common questions

How is tirzepatide different from semaglutide?

Tirzepatide activates two receptors (GIP and GLP-1) while semaglutide activates only one (GLP-1). This dual action produces greater weight loss and blood sugar improvement than GLP-1 drugs alone.

What conditions can tirzepatide treat?

Currently approved for type 2 diabetes, obesity, and sleep apnea. It also shows benefits for heart failure and fatty liver disease, with more indications under investigation.

Read the original research

Insights into the Mechanism of Action of Tirzepatide: A Narrative Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(1), 19-40

View on PubMed ↗Publisher’s paper ↗

Citation

Galindo, Rodolfo J; Cheng, Alice Y Y; Longuet, Christine; Ai, Minrong; Coskun, Tamer; Malik, Raleigh; Peleshok, Jennifer; Levine, Joshua A; Dunn, Julia P. (2026). Insights into the Mechanism of Action of Tirzepatide: A Narrative Review.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(1), 19-40. https://doi.org/10.1007/s13300-025-01804-w